IL1B and age-related macular degeneration: Given that anti-VEGF therapy remains the only approved intervention for AMD and is primarily effective in advanced stages, the authors proposed that inhibiting microglia-derived IL-1β could offer therapeutic benefit by preventing further neovascularization in advanced patients or even forestalling its onset in earlier stages.